BioCryst down on halted Phase IIb
BCRX fell $1.58 (16%) to $8 on Tuesday after reporting that it voluntarily placed on hold a Phase IIb trial of
Gathering data...
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
Gathering data...
BCRX fell $1.58 (16%) to $8 on Tuesday after reporting that it voluntarily placed on hold a Phase IIb trial of